259 related articles for article (PubMed ID: 26180080)
1. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.
Placencio VR; DeClerck YA
Cancer Res; 2015 Aug; 75(15):2969-74. PubMed ID: 26180080
[TBL] [Abstract][Full Text] [Related]
2. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.
Gomes-Giacoia E; Miyake M; Goodison S; Rosser CJ
Mol Cancer Ther; 2013 Dec; 12(12):2697-708. PubMed ID: 24072883
[TBL] [Abstract][Full Text] [Related]
3. The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.
Van De Craen B; Declerck PJ; Gils A
Thromb Res; 2012 Oct; 130(4):576-85. PubMed ID: 22801256
[TBL] [Abstract][Full Text] [Related]
4. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.
Fang H; Placencio VR; DeClerck YA
J Natl Cancer Inst; 2012 Oct; 104(19):1470-84. PubMed ID: 22984202
[TBL] [Abstract][Full Text] [Related]
5. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
6. [Role of plasminogen activator inhibitor type 1 in tumor angiogenesis].
Bajou K; Devy L; Masson V; Albert V; Frankenne F; Noël A; Foidart JM
Therapie; 2001; 56(5):465-72. PubMed ID: 11806282
[TBL] [Abstract][Full Text] [Related]
7. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
8. Use of mouse models to study plasminogen activator inhibitor-1.
Declerck PJ; Gils A; De Taeye B
Methods Enzymol; 2011; 499():77-104. PubMed ID: 21683250
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
12. The plasminogen activator system and cancer.
McMahon B; Kwaan HC
Pathophysiol Haemost Thromb; 2008; 36(3-4):184-94. PubMed ID: 19176991
[TBL] [Abstract][Full Text] [Related]
13. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.
Placencio VR; Ichimura A; Miyata T; DeClerck YA
PLoS One; 2015; 10(7):e0133786. PubMed ID: 26207899
[TBL] [Abstract][Full Text] [Related]
14. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
Bajou K
Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
Durand MK; Bødker JS; Christensen A; Dupont DM; Hansen M; Jensen JK; Kjelgaard S; Mathiasen L; Pedersen KE; Skeldal S; Wind T; Andreasen PA
Thromb Haemost; 2004 Mar; 91(3):438-49. PubMed ID: 14983218
[TBL] [Abstract][Full Text] [Related]
16. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
17. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
18. Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Rømer MU; Kirkebjerg Due A; Knud Larsen J; Hofland KF; Christensen IJ; Buhl-Jensen P; Almholt K; Lerberg Nielsen O; Brünner N; Lademann U
Thromb Haemost; 2005 Oct; 94(4):859-66. PubMed ID: 16270643
[TBL] [Abstract][Full Text] [Related]
19. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
Camani C; Gavin O; Kruithof EK
Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
[TBL] [Abstract][Full Text] [Related]
20. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ; Kitson JL; Silvers WK; Mintz B
Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
